Abzu's keynote:
"RN.AI.Visions."
Given by Lykke Pedersen, Abzu’s Chief Pharma Officer, and Morten Lindow at the 18th Annual Meeting of the Oligonucleotide Therapeutics Society 2022.
On the conference:
OTS is an open, nonprofit forum to foster research and development of oligonucleotide therapeutics.
The Oligonucleotide Therapeutics Society (OTS) Annual Meeting is a forum for the realization of the Society’s mission and goals: To foster academic and industry-based research and development of oligonucleotide therapeutics.
Leaders in the field from across the globe, alongside students, will present on an array of topics, including chemistry, AI / machine learning, genome and RNA editing, and preclinical and clinical research.
RN.AI.Visions.
Oligonucleotide Therapeutics Society 2022 keynote:
We tend to forget that the most disruptive and appealing feature of RNA Therapeutics is its generic platform nature: the ability to design and synthesise oligonucleotides that bind and elicit pharmacology is highly predictable and almost digital in nature.
However, for years, the congenital, digital nature of RNA therapeutics has been overshadowed by more analog and less predictable challenges in delivery and safety. Let’s remember that RNA therapeutics in most cases originates back to the simplicity of base-pairing discovered by Watson and Crick in the early 1950s. A fact that enables description of RNA therapeutics as sequences highly suitable for digitalization.
In this provocative joint talk, Morten, a long time RNA Drug Hunter from Roche and Lykke, from the explainable AI company, Abzu, share their joint visions for how the digital nature of RNA therapeutics and modern AI technology together can change the way we do and think drug discovery in RNA therapeutics.
We will discuss 1) How Pharma’s standard project model needs to be upgraded to take advantage of AI and the sequence nature of RNA Therapeutics, 2) How explainable AI and RNA therapeutics together could close the loop between clinical big data and drug discovery and 3) How a machine learning inspired, data science mindset must pervade drug discovery if we are to get out of the current meager productivity trajectory.
Martin Mathiasen and Lykke Pedersen at OTS.
